Is this you? Create Your Porfile
Avatar

Phillip Alper

Genomics Institute of the Novartis Research Foundation

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Phillip Alper is active.

Explore More

Publication

Featured researches published by Phillip Alper.

Archive | 2008

Compounds and compositions as modulators of GPR119 activity

Phillip Alper; Mihai Azimioara; Christopher Cow; Robert Epple; Songchun Jiang; Gerald Lelais; Pierre-Yves Michellys; Daniel Mutnick; Victor Nikulin

Archive | 2006

Compounds and compositions as tpo mimetics

Thomas H. Marsilje; Wenshuo Lu; Phillip Alper; Daniel Mutnick; Yun He

Bioorganic & Medicinal Chemistry Letters | 2006

Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.

Phillip Alper; Hong Liu; Arnab K. Chatterjee; KhanhLinh T. Nguyen; David C. Tully; Christine Tumanut; Jun Li; Jennifer L. Harris; Tove Tuntland; Jonathan Chang; Perry Gordon; Thomas Hollenbeck; Donald S. Karanewsky

Archive | 2011

COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS

David C. Tully; Agnes Vidal; Daniel Mutnick; Phillip Alper

Archive | 2006

HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS

Phillip Alper; Thomas H. Marsilje; Arnab K. Chatterjee; Wenshuo Lu; Daniel Mutnick; Michael J. Roberts; Yun He

Archive | 2017

composto composições como moduladores da atividade de gpr119

Christopher Cow; Daniel Mutnick; Gerald Lelais; Lucas Westcott-Baker; Mihai Azimioara; Phillip Alper; Pierre-Yves Michellys; Robert Epple; Songchun Jiang; Victor Nikulin

Archive | 2017

compostos e composições como moduladores da atividades de gpr119

Daniel Mutnick; H. Michael Petrassi; Phillip Alper; Pierre-Yves Michellys; Robert Epple; Victor Nikulin

Archive | 2013

Compuestos derivados de azabiciclo[3.2.1]octano; agonista del receptor x fernesoide (fxr); proceso para preparar los compuestos; compuesto intermediario; composicion farmaceutica y combinacion farmaceutica que comporenden un compuesto; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de dislipidemia.

David C. Tully; Paul Vincent Rucker; Phillip Alper; Daniel Mutnick; Donatella Chianelli

Archive | 2011

Compositions et procédés de modulation des récepteurs farnésoïdes x

David C. Tully; Agnes Vidal; Daniel Mutnick; Phillip Alper

Archive | 2010

Composés et compositions pouvant servir de modulateurs de l'activité du gpr119

Phillip Alper; Mihai Azimioara; Christopher Cow; Robert Epple; Gerald Lelais; Daniel Mutnick; Victor Nikulin

Explore More

Collaboration

Dive into the Phillip Alper's collaboration.

Top Co-Authors
Avatar

Daniel Mutnick

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors
Avatar

Robert Epple

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors
Avatar

David C. Tully

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors
Avatar

Victor Nikulin

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors
Avatar

Christopher Cow

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors
Avatar

Mihai Azimioara

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors
Avatar

Pierre-Yves Michellys

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors
Avatar

Arnab K. Chatterjee

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors
Avatar

Songchun Jiang

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors
Avatar

Yun He

Chongqing University

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge